Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Xbrane Biopharma AB (publ)
  6. News
  7. Summary
    XBRANE   SE0007789409

XBRANE BIOPHARMA AB (PUBL)

(XBRANE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Xbrane Biopharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021

10/29/2021 | 02:00am EST

Xbrane Biopharma AB (publ) reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported net loss was SEK 45.47 million compared to SEK 57.74 million a year ago. Basic loss per share was SEK 1.83 compared to SEK 2.99 a year ago. Diluted loss per share was SEK 1.83 compared to SEK 2.99 a year ago. For the nine months, net loss was SEK 155.91 million compared to SEK 162.97 million a year ago. Basic loss per share was SEK 6.75 compared to SEK 9.49 a year ago. Diluted loss per share was SEK 6.75 compared to SEK 9.49 a year ago.


ę S&P Capital IQ 2021
All news about XBRANE BIOPHARMA AB (PUBL)
01/18Xbrane Biopharma changes the date for Interim and Year-end Report
AQ
01/04XBRANE BIOPHARMA AB(OM : XBRANE) dropped from OMX Nordic Small Cap Index
CI
2021Certain Shares of Xbrane Biopharma AB are subject to a Lock-Up Agreement Ending on 28-D..
CI
2021Xbrane Biopharma moves to Nasdaq Stockholm Mid Cap segment
AQ
2021Xbrane has initiated development of two new biosimilar candidates, building an oncology..
AQ
2021Xbrane has initiated development of two new biosimilar candidates, building an oncology..
AQ
2021Xbrane Biopharma releases interim report for January - September 2021
AQ
2021Invitation to presentation of xbrane biopharma's interim report january - september, 20..
AQ
2021Interim Report January – September 2021
PU
2021Xbrane Biopharma releases interim report for January – September 2021
AQ
More news
Financials
Sales 2021 18,7 M 2,02 M 2,02 M
Net income 2021 -225 M -24,2 M -24,2 M
Net cash 2021 445 M 48,0 M 48,0 M
P/E ratio 2021 -9,12x
Yield 2021 -
Capitalization 2 244 M 241 M 242 M
EV / Sales 2021 96,1x
EV / Sales 2022 6,94x
Nbr of Employees 56
Free-Float 64,5%
Chart XBRANE BIOPHARMA AB (PUBL)
Duration : Period :
Xbrane Biopharma AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends XBRANE BIOPHARMA AB (PUBL)
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 89,60 SEK
Average target price 206,00 SEK
Spread / Average Target 130%
EPS Revisions
Managers and Directors
Martin ┼mark Chief Executive Officer
Anette Lindqvist Chief Financial Officer & Head-Investor Relations
Anders Lennart Tullgren Chairman
David Vikstr÷m Chief Technology Officer
Siavash Bashiri Chief Operating Officer & Head-Biosimilars
Sector and Competitors
1st jan.Capi. (M$)
XBRANE BIOPHARMA AB (PUBL)-14.50%244
MODERNA, INC.-36.98%64 900
LONZA GROUP AG-15.65%52 307
IQVIA HOLDINGS INC.-14.60%46 031
SEAGEN INC.-17.50%23 323
ICON PUBLIC LIMITED COMPANY-18.65%20 508